Lupus

Lupus is a chronic autoimmune disease that sees the body’s immune system attack its own tissues and organs. More common in women than men, it can inflame the skin, blood cells, joints, kidneys, brain, heart, and lungs.

Lupus is difficult to diagnose as its many symptoms may mimic those of other conditions. They may be mild or cause significant disability.

Some people are born with a tendency to develop lupus, but it can be triggered without warning by an infection, some prescription drugs or even sunlight. There is no cure, but treatments can manage the symptoms. 

Types of lupus

Risk factors

Signs, symptoms and diagnosis of lupus

Causes of lupus

Treatment of lupus

Our lupus research

Lupus is a difficult disease to diagnose and treat. Hudson Institute researchers are investigating improved ways to detect lupus, and treatments that may control its triggers and better target its symptoms.

Genetic variants that contribute to lupus

Professor Seth Masters researching Childhood lupusIn this project, Professor Masters and his team are sequencing the DNA of patients with childhood-onset lupus, or related conditions. In some cases, alterations have been found in key innate immune genes which contributed to the development of disease. This specific diagnosis helps understand the reason why some children have developed the disease, and points towards which therapy is likely to be most beneficial for them.

 

Lead Researcher | Professor Seth Masters

Developing new treatments for lupus

Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson InstituteMolecular studies. New treatment. Professor Michael Gantier and his team are investigating how localised tissue inflammation evolves into systemic lupus erythematosus (SLE), which sees the immune system attack normally healthy tissue. This disease involves the overproduction of interferons that are thought to drive its causes. Prof Gantier has identified factors that sustain the chronic inflammation initiated byinterferon production and is developing new treatments for lupus including an innovative topical cream applied to affected skin which is currently being tested on participants in a world-first clinical trial. Read more

Lead Researcher | Professor Michael Gantier

Understanding the source of inflammation in lupus

Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute

Molecular studies carried out by Prof Michael Gantier and his team have uncovered a novel mechanism essential to prevent our immune system from attacking normally healthy tissue. They found that patients mutations preventing this mechanism led to lupus, suggesting this is an essential factor protecting against the development of the disease. This program will help the development of more targeted treatments of lupus. Read more

Lead Researcher | Professor Michael Gantier

Controlling the triggers that cause lupus

Lupus collaborators

Support for people with Lupus

Hudson Institute scientists cannot provide medical advice.
Find out more about Lupus.

Share this page